Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience

Background. KRAS mutation is an important predictive and prognostic factor for patients receiving anti-EGFR therapy. An expanded KRAS, NRAS, BRAF, PIK3CA mutation analysis provides additional prognostic information, but its role in predicting bevacizumab efficacy is unclear. The aim of our study was...

詳細記述

書誌詳細

出版年:	Acta Medica Lituanica
主要な著者:	Edita Baltruškevičienė, Ugnius Mickys, Tadas Žvirblis, Rokas Stulpinas, Teresė Pipirienė Želvienė, Eduardas Aleknavičius
フォーマット:	論文
言語:	英語
出版事項:	Vilnius University Press 2016-04-01
主題:	KRAS NRAS BRAF PIK3CA colorectal cancer bevacizumab
オンライン･アクセス:	https://www.journals.vu.lt/AML/article/view/21456